PLK1 and small cell lung carcinoma: Navitoclax has been shown to potentiate the cytotoxicity of BI2536 (a PLK1 inhibitor) in 2D and 3D models of small-cell lung cancer, being able to overcome mitotic slippage and favor apoptosis [75].